Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of aztreonam + avibactam versus meropenem-based therapy for severe multidrug-resistant Gram-negative infections
MOH_2019-01-23_004917Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Aug 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in sepsis, Intra-abdominal infection (IAI), hospital-acquired pneumonia (HAP) and 2 more comparing Aztreonam + avibactam with or without metronidazole with Meropenem with or without colistin (2 arms). Primary endpoint: Primary endpoint not provided in registry extract. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
aztreonamavibactammeropenemcolistinmetronidazole
03
Conditions
sepsisIntra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Gram-negative bacterial infection
Beyond the preview
Go deeper on MOH_2019-01-23_004917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-23_004917.